Intellectual Disability and Psychotropic Medications

被引:2
|
作者
Herzig, Lisa [1 ]
de Lacy, Nina [2 ]
Capone, George [3 ]
Radesky, Jenny [4 ]
机构
[1] Seattle Childrens Hosp, Div Dev Pediat, Seattle, WA 98105 USA
[2] Seattle Childrens Hosp, Div Psychiat & Behav Med, Seattle, WA USA
[3] Kennedy Krieger Inst, Down Syndrome Clin & Res Ctr, Baltimore, MD USA
[4] Univ Michigan, Med Sch, Div Dev Behav Pediat, Ann Arbor, MI 48109 USA
关键词
trisomy; 21; intellectual disability; psychotropic medication; self-injury; ANTIPSYCHOTIC USE; DOWN-SYNDROME; CHILDREN;
D O I
10.1097/DBP.0000000000000613
中图分类号
B84 [心理学]; C [社会科学总论]; Q98 [人类学];
学科分类号
03 ; 0303 ; 030303 ; 04 ; 0402 ;
摘要
CASE: Andrew is a 17-year-old male with trisomy 21, commonly known as Down syndrome, and accompanying severe intellectual disability who presents to your primary care office with his father for the first time to establish care and assistance with transition. Andrew has a history of a complete atrioventricular canal that was repaired as an infant and poorly controlled infantile spasms. Currently, he struggles with constipation, esophageal strictures, medullary nephrocalcinosis, urinary retention, sleep dysregulation, G-tube dependency, and hip dysplasia. Andrew walked at 11 to 12 years of age. Currently, he ambulates on his feet at home and in a wheelchair out in the community. He is nonverbal but can imprecisely sign for "more" and understands a few words. His father reports that his main concern is long-standing nonsuicidal self-injury (NSSI) and aggression. His self-injury consists of head banging against hard objects such as concrete floors and biting or scratching himself to the point of bleeding. Over the past 13 years, he has been prescribed over 10 different psychotropic medications, including various typical and atypical antipsychotics, selective serotonin reuptake inhibitors, benzodiazepines, mood stabilizers, and alpha agonists, all of which were discontinued because of the perception of undesirable side effects or lack of efficacy. His current medications include aripiprazole, olanzapine, levetiracetam, clorazepate, and trazodone. To rule out causes of irritability, you order a brain and spine magnetic resonance imaging, metabolic testing (for causes of NSSI such as Lesch-Nyhan), an autoimmune workup (for causes of pain or inflammation such as juvenile idiopathic arthritis), and hearing/vision testing, which are all normal. Previous testing by subspecialists (he is followed by gastroenterology, sleep medicine, orthopedics, nephrology, neurology, cardiology, and psychiatry) included normal renal ultrasound and no clear sources of gastrointestinal pain. However, key providers are spread among multiple institutions and do not regularly communicate. Andrew lives with his parents, who are highly educated and very dedicated to his health and wellness. His mother travels frequently for work, and his father is Andrew's full-time caregiver. Despite remaining ostensibly positive, his father reports significant caregiver burnout and fatigue. Over the next several months, Andrew continues to experience worsening NSSI necessitating medication changes despite active involvement in applied behavior analysis therapy. During this time, he presents to the emergency department multiple times for irritability and self-injury. On examination, he is aggressive, irritable, has bruises on his forehead and scratches on his skin, and has intermittent vertical gaze deviation that was noticeable to parents. The rest of his physical and neurological examination was unremarkable and revealed no asymmetry, clonus, hyperreflexia, or changes in muscle tone. While examining his extremities, joints, and abdomen, there was no obvious source of pain. What are your next steps? How would you support this family, both in the immediate management of his self-injury and long-term care needs for this medically and behaviorally complex adolescent?
引用
收藏
页码:591 / 593
页数:3
相关论文
共 50 条
  • [1] Management of psychotropic medications in adults with intellectual disability: a scoping review
    Costello, Ashley
    Hudson, Eithne
    Morrissey, Susan
    Sharma, Drona
    Kelly, Dervla
    Doody, Owen
    ANNALS OF MEDICINE, 2022, 54 (01) : 2486 - 2499
  • [2] Psychotropic medication use in adolescents with intellectual disability living in the community
    Doan, Tan
    Ware, Robert
    McPherson, Lyn
    van Dooren, Kate
    Bain, Christopher
    Carrington, Suzanne
    Einfeld, Stewart
    Tonge, Bruce
    Lennox, Nicholas
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2014, 23 (01) : 69 - 76
  • [3] Use of psychotropic medications in adults with intellectual disability: A systematic review and meta-analysis
    Song, Menghuan
    Rubin, Bryn S.
    Ha, Justin W. T.
    Ware, Robert S.
    Doan, Tan N.
    Harley, David
    AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY, 2023, 57 (05) : 661 - 674
  • [4] Prevalence of Psychotropic Medication Use and Psychotropic Polypharmacy in Autistic Adults With or Without Intellectual Disability
    Yoshida, Kazunari
    Lunsky, Yona
    Mueller, Daniel J.
    Desarkar, Pushpal
    JOURNAL OF AUTISM AND DEVELOPMENTAL DISORDERS, 2025, 55 (02) : 457 - 471
  • [5] Prescribing psychotropic drugs to adults with an intellectual disability
    Trollor, Julian N.
    Salomon, Carmela
    Franklin, Catherine
    AUSTRALIAN PRESCRIBER, 2016, 39 (04) : 126 - 130
  • [6] Psychotropic drugs intake in people aging with intellectual disability: Prevalence and predictors
    Garcia-Dominguez, Laura
    Navas, Patricia
    Angel Verdugo, Miguel
    Arias, Victor B.
    Gomez, Laura E.
    JOURNAL OF APPLIED RESEARCH IN INTELLECTUAL DISABILITIES, 2022, 35 (05) : 1109 - 1118
  • [7] Psychotropic medications and adults with intellectual disabilities: care staff perspectives
    Lalor, John
    Poulson, Liz
    ADVANCES IN MENTAL HEALTH AND INTELLECTUAL DISABILITIES, 2013, 7 (06) : 333 - 345
  • [8] Multimorbidity and psychotropic polypharmacy among participants with autism spectrum disorder with intellectual disability
    Espadas, Cristina
    Ballester, Pura
    Londono, Ana Carolina
    Almenara, Susana
    Aguilar, Victor
    Belda, Cesar
    Perez, Enrique
    Peiro, Ana Maria
    PSYCHIATRY RESEARCH, 2020, 292
  • [9] QUALITATIVE EXPLORATION OF PSYCHOTROPIC MEDICATION PRESCRIBING FOR ADULTS WITH INTELLECTUAL DISABILITY
    Sheehan, R.
    Strydom, A.
    Hassiotis, A.
    Morant, N.
    JOURNAL OF INTELLECTUAL DISABILITY RESEARCH, 2019, 63 (07) : 678 - 678
  • [10] Psychotropic medications use and side effects of individuals with intellectual and developmental disabilities
    Charlot, L. R.
    Doerfler, L. A.
    McLaren, J. L.
    JOURNAL OF INTELLECTUAL DISABILITY RESEARCH, 2020, 64 (11) : 852 - 863